Annals of breast cancer and therapy最新文献

Olaparib for Simultaneous Occurrence of Breast Cancer and Ovarian Cancer with BRCA1 奥拉帕尼治疗同时发生的BRCA1型乳腺癌和卵巢癌

Annals of breast cancer and therapy Pub Date : 2023-01-01 DOI: 10.36959/739/528

Tanaka Rina, Sasaki Akinori, Sano Shoko, Mizokami Ken

引用次数: 0

Patterns of Care and Predictors of Survival among DCIS Patients: An NCDB Analysis DCIS患者的护理模式和生存预测因素：NCDB分析

Annals of breast cancer and therapy Pub Date : 2020-10-01 DOI: 10.36959/739/526

Broecker Justine S, Liu Yuan S, Dewey Betsey, Styblo Toncred, Gillespie Theresa S

引用次数: 1

Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. 未满足的临床需求:开发预后生物标志物和精准医学来预测高危乳腺癌的早期肿瘤复发，检测化疗耐药和提高总生存率。

Annals of breast cancer and therapy Pub Date : 2020-05-02 DOI: 10.36959/739/525

Gagan Gupta, Caroline Dasom Lee, Mary L Guye, Robert E Van Sciver, Michael P Lee, Alex C Lafever, Anthony Pang, Angela M Tang-Tan, Janet S Winston, Billur Samli, Rick J Jansen, Richard A Hoefer, Amy H Tang

{"title":"Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.","authors":"Gagan Gupta, Caroline Dasom Lee, Mary L Guye, Robert E Van Sciver, Michael P Lee, Alex C Lafever, Anthony Pang, Angela M Tang-Tan, Janet S Winston, Billur Samli, Rick J Jansen, Richard A Hoefer, Amy H Tang","doi":"10.36959/739/525","DOIUrl":"https://doi.org/10.36959/739/525","url":null,"abstract":"<p><p>Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical prognostic tools evaluate four clinicopathological factors: Tumor size, LN status, pathological stage, and tumor molecular subtype. However, many similarly treated patients with identical residual cancer burden (RCB) following NACT experience distinctly different tumor relapse rates, clinical outcomes and survival. This problem is particularly apparent for incomplete responders with a high-risk RCB classification following NACT. Therefore, there is a pressing need to identify new prognostic and predictive biomarkers, and develop novel curative therapies to augment current standard of care (SOC) treatment regimens to save more lives. Here, we will discuss these unmet needs and clinical challenges that stand in the way of precision medicine and personalized cancer therapy.</p>","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"4 1","pages":"48-57"},"PeriodicalIF":0.0,"publicationDate":"2020-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38049628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Difficult-to-Diagnose Hormone-Negative, Human Epidermal Growth Factor Receptor 2-Positive Poorly-Differentiated Breast Cancer in a Male Patient 难以诊断的激素阴性、人表皮生长因子受体2阳性低分化乳腺癌1例男性患者

Annals of breast cancer and therapy Pub Date : 2020-03-12 DOI: 10.36959/739/524

Kitada Masahiro, Yasuda Shunsuke, A. Masahiro, Yoshida Nana, Okazaki Satoshi, Ishibashi Kei

引用次数: 0

The Lived Experience of African American Women with Lymphedema 非裔美国妇女淋巴水肿的生活经历

Annals of breast cancer and therapy Pub Date : 2019-03-11 DOI: 10.36959/739/522

Collins-Bohler Deborah

引用次数: 0

Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy. Retrospective study in early stage ER positive breast cancer Oncotype DX RS与临床病理危险因素及化疗的相关性。早期ER阳性乳腺癌的回顾性研究

Annals of breast cancer and therapy Pub Date : 2018-11-02 DOI: 10.33582/2640-8198/1005

F. Salih, F. Calaud, K. Rasul, M. Elmistiri, N. Elhadi, Hafez Gazouani, S. Bujassoum

{"title":"Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy. Retrospective study in early stage ER positive breast cancer","authors":"F. Salih, F. Calaud, K. Rasul, M. Elmistiri, N. Elhadi, Hafez Gazouani, S. Bujassoum","doi":"10.33582/2640-8198/1005","DOIUrl":"https://doi.org/10.33582/2640-8198/1005","url":null,"abstract":"Background: Oncotype DX risk score, a clinically validated test that estimates the recurrence and predicts the likelihood of benefit from adjuvant chemotherapy in early ERPR positive, node-negative breast cancer, it is calculated based on characteristics of 21 genes that define the ER status, Her2 neu status, tumor proliferation, and tumor invasion. NCCN guidelines recommend adjuvant endocrine therapy for low RS (<18) and systemic adjuvant chemotherapy for high RS (>30), but no clear consensus about chemotherapy role in intermediate RS [18-30]. The aim of the study: Look for Oncotype Dx correlation, with clinicopathologic risk factors (age, tumor histology, tumor size, tumor grade, ER/PR status, tumor proliferation index) and chemotherapy. We did also evaluate how John Hopkins university recurrence score online tool can be utilized in filtering patient for Oncotype DX testing. Methods: Retrospective records review of approximately 54 patients who had Oncotype DX test during 2012-2017 in National Cancer Center–Qatar. Result: Of 54 patients studied 64.8% had low RS, 27.8% had intermediate RS, and 7.4% had high RS. Univariate analysis showed significant correlation with tumor grade (p<0.003), PR% status (cut-off 1%; p<0.016) and Ki67% (cut-off 20%; p<0.001). There was no significant correlation with patient age, tumor histology or tumor size. In multivariate analysis, only Ki67% predicted the Oncotype DX RS (p<0.028). JHU recurrence score had a moderate association with Oncotype DX RS at strength of agreement 0.524 (Cohen Kappa) Adjuvant chemotherapy treatment correlated significantly with the Oncotype DX RS in both univariate analysis (p < 0.002) and multivariate analysis (p < 0.003) Conclusion: Oncotype RS correlates significantly with the tumor grade, Ki67%, PR status, and chemotherapy treatment. JHU recurrence score has reasonable utility in filtering patient for Oncotype DX testing.","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73474664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Pro-necroptotic agents in cancer therapy 促坏死药物在癌症治疗中的应用

Annals of breast cancer and therapy Pub Date : 2018-10-19 DOI: 10.33582/2640-8198/1004

A. El-Sharkawy, A. Malki

引用次数: 0

Control of breast cancer using metal-containing polymers based on cell line results 利用基于细胞系结果的含金属聚合物控制乳腺癌

Annals of breast cancer and therapy Pub Date : 2018-08-08 DOI: 10.33582/2640-8198/1003

M. Roner, C. Carraher, Kimberly R. Shahi, Alisha Moric-Johnson, Lindsey C. Miller, P. Slawek, Francesca Mosca

引用次数: 1

Long-term outcome data for patients with HER2- positive early-stage breast cancer treated with adjuvant trastuzumab: Benefit outside clinical trial setting HER2阳性早期乳腺癌患者接受辅助曲妥珠单抗治疗的长期结局数据:临床试验外的获益

Annals of breast cancer and therapy Pub Date : 2018-07-07 DOI: 10.33582/2640-8198/1002

Quintyne Ki, B Woulfe, Coffey Jc, Gupta Rk

引用次数: 0